Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.
Benjamin Heyman, MD
Advertisement
Articles by Benjamin Heyman, MD
Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.
Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.
Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma.
Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.
Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.
Advertisement
Latest Updated Articles
Dr. Heyman on the ALPINE Trial in CLLPublished: May 10th 2022 | Updated:
Dr. Heyman on Frontline Treatment Options in Follicular LymphomaPublished: February 21st 2020 | Updated:
Dr. Heyman on the Use of Maintenance Rituximab in Follicular LymphomaPublished: February 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5